Clinical Short-Term Outcome and Hemodynamic Comparison of Six Contemporary Bovine Aortic Valve Prostheses.


Journal

The Thoracic and cardiovascular surgeon
ISSN: 1439-1902
Titre abrégé: Thorac Cardiovasc Surg
Pays: Germany
ID NLM: 7903387

Informations de publication

Date de publication:
10 2020
Historique:
pubmed: 23 1 2019
medline: 16 12 2020
entrez: 23 1 2019
Statut: ppublish

Résumé

Conventional stented valves (CV) remain gold standard for aortic valve disease. Bovine prostheses have been improved and rapid deployment valves (RDV) have arrived in the recent decade. We compare clinical and hemodynamic short-term outcome of six bovine valves. We retrospectively evaluated 829 consecutive patients (all-comers) receiving bovine aortic valve replacement (AVR). Four CV from different manufacturers (Mitroflow, Crown, Perimount, Trifecta) and two RDV (Perceval, Intuity) were compared in terms of pre-, intra-, and postprocedural data. A risk model for mortality was created. All valves reduced gradients. From 23 mm, all CV showed acceptable gradients. Twenty-one millimeter Mitroflow/Perceval and 19 mm Crown showed above-average gradients. As baseline data differed, we performed propensity matching between aggregated isolated CV and RDV groups. Cardiopulmonary bypass (CPB), clamp, and surgery times were shorter with RDV (87.4 ± 34.0 min vs 111.0 ± 34.2, 54.3 ± 21.1 vs 74.9 ± 20.4, 155.2 ± 42.9 vs 178.0 ± 46.8, Isolated bovine AVR has low mortality. Valves ≥ 23 mm show comparable gradients while the valve model matters < 23 mm. RDV should be used with care. Procedure-related times are shorter than those of CV but pacemaker implantation and neurologic events are more frequent (Perceval). Early mortality is low and valve performance comparable to CV.

Sections du résumé

BACKGROUND
Conventional stented valves (CV) remain gold standard for aortic valve disease. Bovine prostheses have been improved and rapid deployment valves (RDV) have arrived in the recent decade. We compare clinical and hemodynamic short-term outcome of six bovine valves.
METHODS
We retrospectively evaluated 829 consecutive patients (all-comers) receiving bovine aortic valve replacement (AVR). Four CV from different manufacturers (Mitroflow, Crown, Perimount, Trifecta) and two RDV (Perceval, Intuity) were compared in terms of pre-, intra-, and postprocedural data. A risk model for mortality was created.
RESULTS
All valves reduced gradients. From 23 mm, all CV showed acceptable gradients. Twenty-one millimeter Mitroflow/Perceval and 19 mm Crown showed above-average gradients. As baseline data differed, we performed propensity matching between aggregated isolated CV and RDV groups. Cardiopulmonary bypass (CPB), clamp, and surgery times were shorter with RDV (87.4 ± 34.0 min vs 111.0 ± 34.2, 54.3 ± 21.1 vs 74.9 ± 20.4, 155.2 ± 42.9 vs 178.0 ± 46.8,
CONCLUSION
Isolated bovine AVR has low mortality. Valves ≥ 23 mm show comparable gradients while the valve model matters < 23 mm. RDV should be used with care. Procedure-related times are shorter than those of CV but pacemaker implantation and neurologic events are more frequent (Perceval). Early mortality is low and valve performance comparable to CV.

Identifiants

pubmed: 30669172
doi: 10.1055/s-0038-1676853
doi:

Types de publication

Comparative Study Journal Article Observational Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

557-566

Informations de copyright

Thieme. All rights reserved.

Déclaration de conflit d'intérêts

None.

Auteurs

Martin Hartrumpf (M)

Department of Cardiovascular Surgery, Heart Center Brandenburg, Brandenburg Medical School, University Hospital Bernau, Bernau bei Berlin, Germany.

Ralf-Uwe Kuehnel (RU)

Department of Cardiovascular Surgery, Heart Center Brandenburg, Brandenburg Medical School, University Hospital Bernau, Bernau bei Berlin, Germany.

Filip Schroeter (F)

Department of Cardiovascular Surgery, Heart Center Brandenburg, Brandenburg Medical School, University Hospital Bernau, Bernau bei Berlin, Germany.

Robert Haase (R)

Department of Cardiovascular Surgery, Heart Center Brandenburg, Brandenburg Medical School, University Hospital Bernau, Bernau bei Berlin, Germany.

Magdalena L Laux (ML)

Department of Cardiovascular Surgery, Heart Center Brandenburg, Brandenburg Medical School, University Hospital Bernau, Bernau bei Berlin, Germany.

Roya Ostovar (R)

Department of Cardiovascular Surgery, Heart Center Brandenburg, Brandenburg Medical School, University Hospital Bernau, Bernau bei Berlin, Germany.

Johannes M Albes (JM)

Department of Cardiovascular Surgery, Heart Center Brandenburg, Brandenburg Medical School, University Hospital Bernau, Bernau bei Berlin, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH